Last10K.com

Dbv Technologies S.A. (DBVT) SEC Filing 6-K Foreign Issuer report for the period ending Friday, February 22, 2019

Dbv Technologies S.A.

CIK: 1613780 Ticker: DBVT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of February 2019

Commission File Number: 001-36697

 

 

DBV TECHNOLOGIES S.A.

(Translation of registrant’s name into English)

 

 

177-181 avenue Pierre Brossolette

92120 Montrouge France

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒  Form 20-F            ☐  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 


EXPLANATORY NOTE

On February 22, 2019, DBV Technologies S.A. announced that detailed results from its pivotal Phase III clinical trial evaluating the efficacy and safety of Viaskin Peanut for the treatment of peanut-allergic children 4 to 11 years of age were published in The Journal of the American Medical Association (“JAMA”). DBV Technologies S.A. prepared a presentation in connection with the results published in JAMA, which it intends to use in conferences and meetings with investors. Copies of the press release and the presentation are filed with this Report of Foreign Private Issuer on Form 6-K as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  DBV TECHNOLOGIES S.A.
Date: February 22, 2019   By:  

/s/ David Schilansky

  Name:   David Schilansky
  Title:   Deputy Chief Executive Officer

View differences made from one to another to evaluate Dbv Technologies S.A.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Dbv Technologies S.A..

Continue

Assess how Dbv Technologies S.A.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Dbv Technologies S.A.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Material Contracts, Statements, Certifications & more

Dbv Technologies S.A. provided additional information to their SEC Filing as exhibits

Ticker: DBVT
CIK: 1613780
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001193125-19-048310
Submitted to the SEC: Fri Feb 22 2019 4:11:13 PM EST
Accepted by the SEC: Fri Feb 22 2019
Period: Friday, February 22, 2019
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/dbvt/0001193125-19-048310.htm